Blog

BioLife Solutions CryoStor® Cell Freeze Media Highlighted in Mayo Clinic/MD Anderson Journal Article on Preservation of Patient-Derived Xenografts for Cancer Research

On March 13, 2018 BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced that the performance of its proprietary, cGMP CryoStor cell freeze media was reported in the journal Laboratory Investigation. In multiple comparisons of preservation efficacy of patient-derived xenograft (PDX) tumors,…

Read More

BioLife Solutions Announces Fourth Quarter and Full Year 2017 Financial Results

BioLife Solutions Announces Fourth Quarter and Full Year 2017 Financial Results  Revenue Increased 39% for the Quarter and 34% for the Year Achieves Positive Cash Flow from Operations for the Year Reaffirms Guidance for 2018 Operating Profit On March 8, 2018 BioLife Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue…

Read More

BioLife Solutions to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Business Update on March 8, 2018

BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media (“BioLife” or the “Company”), announced that the Company’s fourth quarter and full year 2017 financial results will be released after market close on Thursday, March 8, 2018, and that the Company will host a…

Read More

BioLife Solutions Executes OEM Agreement with MilliporeSigma

BioLife Solutions Executes OEM Agreement with MilliporeSigma  Private Labeled CryoStor® Cell Freeze Media and HypoThermosol® Cell and Tissue Storage and Shipping Media Distributed to Worldwide Biotech Research Market On February 13, 2018 BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media (“BioLife” or the “Company”), announced that it has…

Read More
CGTI Alireza Article Blog Post

Biopreservation Best Practices: A Cornerstone in the Supply Chain of Cell-based Therapies – MSC Model Case Study

Mesenchymal stromal cells (MSCs) are prime candidates for regenerative medicine and therapeutic applications due to both their potent immuno- modulatory function and a unique ability to proliferate and differentiate into a variety of cell lineages. However, the stresses incurred during biopreservation/stability intervals (non-frozen and cryopreserved), including transit to and from the clinic can render MSCs ineffective and potentially unsafe.…

Read More

BioLife Solutions Announces Preliminary 2017 Revenue Increase of 34% to $11 Million

Q4 2017 Preliminary Revenue Reaches Record $3.1 Million, up 39% over Q4 2016 On January 4, 2018 BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical-grade cell and tissue hypothermic storage and cryopreservation freeze media, announced preliminary Q4 and full year 2017 revenue and provided additional operational updates and financial guidance for 2018.…

Read More
Iovance Blog Post

BioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics

On December 13, 2017 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media (“BioLife” or the “Company”), announced that it has executed an agreement to supply its CryoStor® cell freeze media and HypoThermosol® cell storage and shipping media to Iovance Biotherapeutics, Inc. (“Iovance”) (NASDAQ: IOVA). Iovance is…

Read More
TissueGene Blog Post

Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea

Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea A huge congratulations to BioLife customer TissueGene / Kolon Life Science on their first patient use of CryoStor – powered Invossa, a novel cell-mediated therapy for degenerative arthritis. Invossa is the world’s first gene therapy for treating osteoarthritis of the knee, in which the cartilage that cushions…

Read More